Mesoblast Ltd
USUSDMesoblast Ltd (AU:MSB) — Biotechnology: Biological Products (No Diagnostic Substances). Брой борси, на които се търгуват акциите на компанията: 2. На тази страница — цена и график, дивиденти, най-големи акционери и история на броя на акциите.
За компанията
- Уебсайт
- mesoblast.com
- Сектор
- Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
- Централа
- MELBOURNE, VICTORIA, Australia
- Изпълнителен директор
- Silviu Itescu
- Служители
- 108
- Акции в обращение
- 1.3 млрд към 2026-06-30
- Свободно търгуеми акции
- 861.1 млн
- Пазарна капитализация
- 1.48 млрд USD
- Инсайдери
- 36.28%
- Институционални инвеститори
- 17.44%
- Отрасъл (SIC)
- Biological Products, (No Diagnostic Substances)
- ISIN
- AU000000MSB8
- Коефициент на изплащане
- 0%
- FCF
- −60.6 млн USD
- Дълг
- 127 млн USDнетни парични средства
- Дивидентна история
- —
- Печалба, FCF и изплатени дивиденти — за 12-те месеца до 31.12.2025 (последният отчет на компанията).
Описание
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers remestemcel-L-rknd, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, Duchenne muscular dystrophy, and biologic refractory inflammatory bowel disease, as well as ulcerative colitis and Crohn's disease; Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease; and Revascor for the treatment of hypoplastic left heart syndrome. The company is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; MPC-150-IM for the treatment or prevention of chronic heart failure; Ryoncil for the treatment of pediatric SR-aGVHD; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM; Grünenthal GmbH to develop and commercialize MPC-06-ID for the treatment of chronic low back pain due to degenerative disc disease in patients; and JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.
Дивиденти
Не са намерени дивидентни плащания (проверено 10.10.2026). Вероятно компанията не изплаща дивиденти.
Новини тази седмица
Все още няма новини от сайта на компанията.
Най-големи притежатели
| Притежател | Дял | Акции | Дата на доклада |
|---|---|---|---|
| Itescu (Silviu) (Chief E… | ≈6.23% | 80.84 млн | 2026-07-17 |
| VANGUARD STAR FUNDS-Vang… | 1.05% | 13.66 млн | 2026-04-30 |
| VANGUARD TAX-MANAGED FUN… | 0.62% | 8.01 млн | 2026-06-30 |
| iShares Trust-iShares Co… | 0.53% | 6.88 млн | 2026-07-31 |
| Rose (Eric) (Director (N… | ≈0.52% | 6.75 млн | 2026-01-09 |
| DFA INVESTMENT TRUST CO-… | 0.36% | 4.68 млн | 2026-04-30 |
| VANGUARD Intl Eqy. INDEX… | 0.27% | 3.51 млн | 2026-04-30 |
| iShares Trust-iShares MS… | 0.24% | 3.07 млн | 2026-07-31 |
| SCHWAB STRATEGIC TRUST-S… | 0.15% | 1.99 млн | 2026-05-31 |
| Dimensional ETF Trust-Di… | 0.11% | 1.38 млн | 2026-04-30 |
| iShares Trust-iShares Co… | 0.09% | 1.23 млн | 2026-07-31 |
| SPDR INDEX SHARES Fd.S-S… | 0.09% | 1.19 млн | 2026-08-31 |
| Bell (Jane Catherine) (D… | ≈0.05% | 622 492 | 2025-02-28 |
| Burns (William) (Indepen… | ≈0.02% | 226 250 | 2025-10-21 |
| Legato Capital Managemen… | 0.01% | 47 380 | 2022-06-30 |
| Cobley (Lyn Elizabeth) (… | ≈0% | 63 000 | 2026-01-09 |
